Stockreport

Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? [Yahoo! Finance]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF TCR Bispecific candidates IMA402 and IMA401, which demonstrated objective responses in challenging solid tumor indications. Early findings revealed treatment responses [Read more]